Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | AHCY | P23526 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13964740 | 1.00 | ADORA2A (0.58) | ADORA2AADORA2BHIF1AAHCYTMEM97 | |
| SCHEMBL19190143 | 1.00 | ADORA2A (0.58) | ADORA2AADORA2BHIF1AAHCYTMEM97 | |
| SCHEMBL13974841 | 1.00 | ADORA2A (0.58) | ADORA2AADORA2BHIF1AAHCYTMEM97 | |
| SCHEMBL13964754 | 0.90 | ADORA2A (0.52) | ADORA2AADORA2BADORA3 | |
| SCHEMBL20558074 | 0.89 | P2RY12 (0.48) | ADORA2AADORA2BADORA3 | |
| SCHEMBL26435554 | 0.89 | ADORA3 (0.54) | ADORA2AADORA2BADORA3 | |
| SCHEMBL23621389 | 0.87 | LMNA (0.60) | ADORA2AADORA2BADORA3 | |
| SCHEMBL21063207 | 0.87 | LMNA (0.60) | ADORA2AADORA2BADORA3 | |
| SCHEMBL9294393 | 0.87 | LMNA (0.60) | ADORA2AADORA2BADORA3 | |
| SCHEMBL21625242 | 0.87 | LMNA (0.60) | ADORA2AADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987437-B2 | Processes and intermediates for preparing anti-HIV Agents | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987437-B2 | Processes and intermediates for preparing anti-HIV Agents | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20120296076-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | GILEAD SCIENCES, INC. | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120296076-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | SAMHD1, DHPS, LSS | ADORA2A 3746/4885ADORA2B 4029/4885HIF1A 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.